Jim Cramer reveals his No. 1 rule to buying a stock, and the different tactics that go into investing and trading. » Read More
Jim Cramer shares his advice on how investors can shield their portfolios from painful pullbacks. » Read More
Jim Cramer explains important role cash plays in a portfolio, and how he outperformed the market as a money manager. » Read More
Jim Cramer shares his experience of getting burned and the importance of discipline. » Read More
There may be way too much anticipation built up around Trump’s tax reform talk.
The bull rally may be strong, but the long-term outlook appears weak and uncertain, Vanguard founder Jack Bogle tells CNBC.
CNBC PRO used crowdsourced earnings platform Estimize to find the stocks with the best chance at beating the Street.
International mining giant Freeport-McMoRan is up 104 percent in the past year, but some analysts say it’s still a buy.
Heal is a start-up revolutionizing health care with doctors on call. Today it announces national expansion plans.
Balancing active and passive approaches to portfolio management can deliver the best of both worlds while compensating for any downsides.
Tribune Media, one of the largest U.S. television station operators, said on Tuesday that activist investor Starboard Value had taken a 6.6 percent stake in the company.
TipRanks identified the corporate insiders with the best-performing track record and found out which stocks they like right now.
Barry Rosenstein's Jana Partners has teamed up with former Bulgari boss Francesco Trapani to nab a stake and three board seats.
Buybacks keep rolling along, but here is why they are no panacea for all of the market's problems.
Bloomin' Brands closed 43 stores on Feb. 15, according to the company.
The major U.S. equity indexes weren't the only ones making history on Tuesday.
Shares of Scripps Networks Interactive rose Tuesday, after the company reported a revenue beat for the fourth quarter.
Shares of Apple hit an all-time high Tuesday, setting a fresh record for the second time this year after nearly two years without a new high.
Momenta says Pfizer, a key supplier for its multiple sclerosis drug, has received a warning letter from the Food and Drug Administration.
Vanguard founder and former CEO Jack Bogle shares his views on the market.
Two popular biotech exchange-traded funds have been on a tear lately, and some strategists see more upside ahead.
Despite a rally that has sent the S&P 500 up a gaudy 5 percent, Goldman is sticking to its fairly pessimistic call for the full year.
Macy's CEO Terry Lundgren sat down with CNBC for an exclusive conversation on what's ahead for the U.S. retailer.
Improving economic data, wider market volume and Trump administration policy expectations are pushing stocks, Mohamed El-Erian says.
Get the best of CNBC in your inbox